A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 05 May 2017
At a glance
- Drugs AZD-1775 (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 01 May 2017 Planned initiation date changed from 30 Apr 2017 to 25 May 2017.
- 20 Apr 2017 Planned initiation date changed from 1 Jan 2017 to 30 Apr 2017.
- 06 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as Protocol moved to Disapproved .